Ligand Pharmaceuticals (LGND) said Thursday its Verona Pharma partner has received approval for Ohtuvayre from the US Food and Drug Administration to treat chronic obstructive pulmonary disease in adult patients in more than 20 years.
The company has earned a milestone payment of $5.8 million upon the regulator's approval of Ohtuvayre, while the commercial launch is expected during Q3, Ligand added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments